1. Multimodal integration of image, epigenetic, and clinical data to predict BRAF mutation status in melanoma
   Lucas Schneider et al, 2023, European Journal of Cancer CrossRef
2. Oncogenic BRAF and p53 Interplay in Melanoma Cells and the Effects of the HDAC Inhibitor ITF2357 (Givinostat).
   Adriana Celesia et al, 2023, Int J Mol Sci CrossRef
3. Primary Undifferentiated/Dedifferentiated Cutaneous Melanomas—A Review on Histological, Immunohistochemical, and Molecular Features with Emphasis on Prognosis and Treatment
   Dana Antonia Țăpoi et al, 2023, IJMS CrossRef
4. Exploring the In Vitro and In Vivo Therapeutic Potential of BRAF and MEK Inhibitor Combination in NRAS-Mutated Melanoma
   Heike Niessner et al, 2023, Cancers CrossRef
5. Incidence of BRAF mutations in cutaneous melanoma: histopathological and molecular analysis of a Ukrainian population
   Oleksandr Dudin et al, 2023, Melanoma Management CrossRef
6. Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapy
   Francisco Meraz-Torres et al, 2024, J Exp Clin Cancer Res CrossRef
7. Assessment of RAS-RAF-MAPK Pathway Mutation Status in Healthy Skin, Benign Nevi, and Cutaneous Melanomas: Pilot Study Using Droplet Digital PCR
   Elena-Georgiana Dobre et al, 2024, IJMS CrossRef
8. A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma
   Xiaoting Wei et al, 2024, European Journal of Cancer CrossRef
9. Melanoma genomics – will we go beyond BRAF in clinics?
   Justyna Mirek et al, 2024, J Cancer Res Clin Oncol CrossRef
10. The relationship of clinical and morphological parameters with the BRAF status of the tumor in patients with stage I skin melanoma
    K. S. Titov et al, 2024, vmirvz CrossRef
11. Comprehensive Breslow thickness (BT)-based analysis to identify biological mechanisms associated with melanoma pathogenesis
    Yuan-jie Liu et al, 2025, International Immunopharmacology CrossRef